DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue S 1 · Volume 30 · January 1997 DOI: 10.1055/s-002-6366

Editorial

  • 1
    Linden, M.:

    Phase IV Research and Drug Utilization Observation Studies

    • Original Paper

  • 4
    Schäfer, H.:

    Post-Approval Drug Research: Objectives and Methods

  • 9
    Zaninelli, R.; Meister, W.:

    The Treatment of Depression with Paroxetine in Psychiatric Practice in Germany:

  • 21
    Laux, C.; Baier, D.:

    Quality-Monitoring of Psychotropic Drug Therapy in Post-Marketing Surveillance

  • 28
    Dittmann, R. W.; Linden, M.; Osterheider, M.; Schaaf, B.; Ohnmacht, U.; Weber, H.-J.:

    Antidepressant Drug Use: Differences between Psychiatrists and General Practitioners

  • 35
    Linden, M.; Baier, D.; Gothe, H.; Kohnen, R.:

    What Happens to Patients After the End of a Clinical Trial?

  • 44
    Schaaf, B.; Linden, M.; Weber, H.-J.:

    An Investigation of the Representativity of Neuropsychiatrists and their Patients in a Drug Utilization Observation Study on Fluoxetine

  • 52
    Lehmann, E.; Klieser, E.:

    Drug Monitoring Studies as a Method of Analyzing Response Criteria

  • 57
    Ahrens, B.:

    Mortality Studies and the Effectiveness of Drugs in Long-term Treatment

  • 62
    Herbold, M.:

    International Guidelines on Post-authorisation Research and Surveillance

  • 65
    Linden, M.; Baier, D.; Beitinger, H.; Kohnen, R.; Osterheider, M.; Philipp, M.; Reimitz, D. E.; Schaaf, B.; Weber, H. J.:

    Guidelines for the Implementation of Drug Utilization Observation (DUO) Studies in Psychopharmacological Therapy